Take a trial of UK to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2009 2010 2011 2012 2013 2014 TTM 2015E 2016E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -28.9%

FINANCIAL BRIEF: For the six months ended 30 June 2015, Silence Therapeutics plc revenues decreased from L7K to L0K. Net loss decreased 26% to L4.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Unallocated Items segment loss decrease of 46% to L962K, RNAi therapeutics segment loss decrease of 17% to L3.2M. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Jun '15) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2015
31st Dec 2016

Price Target: 2.79
(+63.91% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
1 brokers Broker Consensus Trend
Broker Recommendations for Silence Therapeutics
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 0 1

Named Brokers and Analysts
Canaccord Genuity Samuel Hosseini , N+1 Singer Jens Lindqvist , Virtua Research (Historical) , and 1 unnamed other

Profile Summary

Silence Therapeutics plc is a United Kingdom-based drug development company. The Company is engaged in the development and delivery of ribonucleic acid (RNA) therapeutics. The Company's RNA technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company's technology is in the clinic and has been used in Phase II trials. Its gene silencing technology is designed to regulate expression of various genes and the Company has its own delivery systems targeting a range of organs and cell types. Its RNA interference (RNAi) platform is known as AtuRNAi. The Company's delivery systems deliver both short interfering RNA (siRNA) and messenger RNA (mRNA). The Company has a genetic toolkit with its own therapeutic payloads to modulate gene expression up, as well as down in pre-clinical in vivo models.

Directors: Ali Mortazavi (CEO) , Timothy Freeborn (CFO) 54, Lars Karlsson (EDR) 54, Michael Khan (OTH) , Stephen Parker (NEC) 56, Alistair Gray (NED) 67, Simon Sturge (NED) 56,

No. of Employees: 51 No. of Shareholders: n/a

Last Annual December 31st, 2014
Last Interim June 30th, 2015
Incorporated November 18, 1994
Public Since January 5, 2010
Shares in Issue 69,801,624
Free Float 38.5m (55.1%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Intl-aim All Share , FTSE Intl-aim 100 ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

Address 1 Lyric Square, LONDON, W6 0NB, United Kingdom
Web http://silence-therapeutics.com
Phone +44 20 37009711
Contact Timothy Freeborn (Chief Financial Officer, Finance Director, Secretary, Director)
Auditors PricewaterhouseCoopers LLP

SLN Share Price Performance SLNQuote
-0.1  -0.1%
Traded 2:03pm · Minimum 15 min delayed · NMS: 1.50k

Latest SLN News Announcements (delayed)

Upcoming SLN Events
Tuesday 31st May, 2016 (estimate)
Silence Therapeutics PLC Annual Shareholders Meeting

Recent ↓
Thursday 13th August, 2015
Silence Therapeutics PLC at Canaccord Genuity Growth Conference
Monday 1st June, 2015
Silence Therapeutics PLC Annual Shareholders Meeting
Tuesday 19th May, 2015
Silence Therapeutics PLC at Biocentury BioEquity Europe
Thursday 2nd April, 2015
Silence Therapeutics PLC Secondary Public Offering Pricing
Tuesday 16th September, 2014
Half Year 2014 Silence Therapeutics PLC Earnings Release
Friday 27th June, 2014
Silence Therapeutics PLC Annual Shareholders Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.

Should you buy SLN

Access SLN Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis